Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TVB-2640 and Enzalutamide in mCRPC
NCT05743621Phase 1Active, not recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Nov 2023
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of denifanstat in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Weill Cornell Medicine. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Nov 2023; status: active, not recruiting.
02
Drugs
denifanstat
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05743621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05743621.